Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Corgenix Medical Corp.
Collaboration for aspirin-resistance testing announced
December 7th, 2004
Corgenix Medical Corp. (CONX) and AspirinWorks, a division of Creative Clinical Concepts, Inc., (CCC), both headquartered in Denver, Colorado, announced that together they have entered into a license agreement with McMaster University (McMaster), Hamilton, Ontario, providing Corgenix and CCC exclusive rights to the propriety technology owned by McMaster for the development, manufacturing, and marketing of innovative diagnostic tests specific to the pathway by which aspirin acts on platelets. This technology has demonstrated the ability to assess an individual's relative risk for heart attack by measuring the person's degree of aspirin resistance. The...
Source: Cardiovascular Business Week (2004-12-07)
|
